Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CX-2051 · 1 trial · 1 indication
The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level
The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level
| Arm | Type | Description |
|---|---|---|
| CX-2051 | EXPERIMENTAL | - |
| CX-2051 + bevacizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CX-2051 | DRUG | Investigational drug |
| Bevacizumab | DRUG | IV infusion |
Inclusion Criteria: * Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Measurable disease per RECIST v1.1 * Consent to fresh biopsy or if medically contraindicated, recent (with...
CX-2051 is an investigational small molecule being developed for the treatment of solid tumors in adults. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in a first-in-human trial for advanced solid tumors.
CX-2051 targets EpCAM, a protein that is often overexpressed on the surface of many solid tumor cells. By targeting EpCAM, the drug aims to deliver its therapeutic effect specifically to cancer cells while potentially sparing normal tissues.
CX-2051 is being developed by CytomX Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CTMX. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced solid tumors.
CX-2051 is currently in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and preliminary efficacy of the drug in patients with advanced solid tumors.
CX-2051 is being evaluated in a Phase 1 clinical trial with the identifier NCT06265688, titled "First In Human Study of CX-2051 in Advanced Solid Tumors." This trial is currently recruiting participants in the United States and aims to enroll approximately 160 patients with solid tumors.
CX-2051 is a unique investigational drug candidate developed by CytomX Therapeutics. It is not known to be the same as any other approved or investigational drug. Its distinct mechanism of targeting EpCAM sets it apart from other cancer therapies currently in development.